SANSIMEON INC
Scaling Single-Cell Sequencing. Accelerating Cures.
WILMINGTON, United States · Founded 2023 · $1.6M raised
- Headquarters
- WILMINGTON, Delaware
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- sansimeon.bio
- Total Funding
- $1.6M
About
Sansimeon is a biotechnology company pioneering a high-throughput, streamlined platform for scalable single-cell sequencing that can directly process complex clinical samples such as whole blood and bone marrow aspirates without compromising performance. The platform supports immune profiling via TCR repertoire analysis, genome-wide CRISPR screening, and personalized medicine applications. Technologies originated from research at Massachusetts General Hospital (Harvard Medical School). Applications include biomarker discovery, drug target identification, cell therapy development, and clinical trial optimization.
Summary
SANSIMEON INC is a Biotech company based in WILMINGTON, United States, founded in 2023. It has raised $1.6M in total.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...